Skip to content

Carrier

Blue Cross Blue Shield of Massachusetts

Blue Cross and Blue Shield of Massachusetts, Inc. · Drug benefit: Its own pharmacy operations; CVS Caremark manages one of its formularies · 3 documents cited · Read September 2026

Ended GLP-1 coverage for obesity from January 2026 renewals, as an exclusion that can't be appealed, unless a large employer buys it back.

American GLP, Publisher · Who writes this site

Blue Cross Blue Shield of Massachusetts made one of the clearest calls of any insurer: from plan renewals starting January 1, 2026, it stopped covering GLP-1s except for type 2 diabetes. Saxenda, Wegovy and Zepbound are out for obesity, even for people already taking them.

It also says the exclusion can't be appealed. That changes what a denial means here: it's a benefit your plan no longer has, not a clinical call your doctor can argue with.

The one way back is the employer. A company with more than 100 employees can keep the coverage by buying a rider, and Blue Cross publishes the criteria it uses for those groups.

What about Wegovy for heart risk?

Blue Cross answered that for doctors in May 2025: because it's excluding every GLP-1 for obesity from the pharmacy benefit, Wegovy for a heart condition isn't covered either, unless the employer bought the rider.

If your employer kept the rider, what are the rules?

Policy 572 asks for a BMI of 30, or 27 with a weight-related condition, and six months in a weight-loss program. The first approval runs six months and renewals twelve, with at least 5% weight loss needed to continue. Fills are one month at a time and can't go through mail order.

Members on the Focused formulary can't get these drugs for obesity at all, and there's no medical-necessity review for them.

Every claim above, with the document behind it

These are the policies we opened and the month we opened them. Each one carries its own policy number and effective date on its face, and those are printed here as the document shows them.

"We've made the decision to end coverage for GLP-1 medications, except for type 2 diabetes. This change will take effect upon your plan renewal, starting January 1, 2026."

Blue Cross Blue Shield of Massachusetts, GLP-1 Coverage (member page) · source

Asked whether a member can appeal the change with their doctor: "No. This is a benefit exclusion that can’t be appealed."

Blue Cross Blue Shield of Massachusetts, GLP-1 Coverage (member page) · source

"If your company has more than 100 employees, your employer will have the option to continue coverage. If they choose not to, upon plan renewal starting January 1, 2026, Wegovy, Saxenda, and Zepbound will no longer be covered, even if you're currently using them."

Blue Cross Blue Shield of Massachusetts, GLP-1 Coverage (member page) · source

On Wegovy for a cardiovascular condition: "No. Because we are excluding all GLP-1s for obesity (Saxenda, Wegovy, Zepbound) from our pharmacy benefits, this medication would no longer be covered for our member unless their employer purchased a rider to maintain coverage."

Blue Cross Blue Shield of Massachusetts, provider news: GLP-1 medications for obesity, coverage update, effective May 2025 · source

For rider groups: "Initial approval: 6 months; Continuation: 12 months," fills "limited to a 1-month supply (28 to 30 days) per fill," and "All GLP1s + GIP prescriptions are excluded through the mail order pharmacy benefit." Renewal needs "Documented weight loss of at least 5% of baseline body weight".

Blue Cross Blue Shield of Massachusetts, Pharmacy Medical Policy 572, effective July 2026 · source

"For members with the BCBSMA Focused formulary, GLP-1 and GLP-1/GIP medications for the treatment of obesity and other FDA approved medical indications are not a covered benefit. The medical necessity review process is not available."

Blue Cross Blue Shield of Massachusetts, Pharmacy Medical Policy 572, effective July 2026 · source

What these documents cannot tell you

Everything above is what Blue Cross Blue Shield of Massachusetts publishes. None of it establishes what your own plan does, and the gap between those two things is wider than a carrier policy makes it look.

  • Whether your employer bought the rider isn't public. Ask HR or check your plan's benefit summary.
  • Policy 572 doesn't apply to Blue Cross's Medicare Advantage plans.
  • A self-funded employer plan administered by Blue Cross can set its own rules.
  • None of this is legal or medical advice. Your plan documents and your notice govern your case.

Where this comes from

  1. Blue Cross Blue Shield of Massachusetts, GLP-1 Coverage (member page) — Open the document
  2. Blue Cross Blue Shield of Massachusetts, provider news: GLP-1 medications for obesity, coverage update, effective May 2025 — Open the document
  3. Blue Cross Blue Shield of Massachusetts, Pharmacy Medical Policy 572, effective July 2026 — Open the document

Where to go next

American GLP is not a law firm, an insurer, a government office or a clinician, and nothing here is legal or medical advice. This page describes what Blue Cross Blue Shield of Massachusetts publishes. It is not affiliated with Blue Cross and Blue Shield of Massachusetts, Inc., and your own plan documents and your own notice govern your case. Policies carry effective dates and change — read the sources before you act.